Cas9 mRNA Design Optimization
CleanCap   Technology: Leading the way in mRNA™​
®

mRNA capping is a critical aspect of creating viable mRNA constructs that will remain biologically active and avoid self/non-self intracellular responses. TriLink scientists understood the importance of this and realized that the current capping methods of using mCAP, ARCA or enzymatic capping are inadequate due to lowcapping efficiencies (mCAP/ARCA) or high cost (enzymatic).

CleanCap   – A Chemist’s Solution to a Biologist's Problem
®

The unique combination of expertise in synthetic organic chemistry and pioneering knowledge in mRNA at TriLink enabled us to invent a chemical solution for a biological problem. 

  • High capping efficiencies (94%+) resulting in more active mRNA

  • Yields a natural Cap 1 Product

    • Cap 1 does not activate Pattern Recognition Receptors(1,2,3)

    • Important for in vivo work with notable translational improvements over Cap 0 structure(4)

  • "One pot" co-transcriptional reaction to produce a Cap 1 structure vs multiple purifications steps required for enzymatic Cap 1

  • Cap-2 analogs will be available soon. Other modifications are possible, contact us.

  • CleanCap technology is featured in the following products:

ARCA EGFP mRNA
CleanCap EGFP mRNA

CHO Cells, 6 minute fusion with Fuse-It-mRNA kit, 1 ug mRNA, Analysis at 72 hours post fusion

Foreskin fibroblast cells, 10 minute fusion with Fuse-It-mRNA kit, 1ug mRNA analysis at 24 hours post fusion

iPS derived cardiomyoctyes, 10 minute fusion with Fuse-It-mRNA kit, 1ug mRNA, analysis at 24 hour post fusion

CleanCap vs. ARCA vs. Enzymatic Capping
Exceptional Capping Efficiency in a Rapid Co-Transcriptional Reaction
Capping Cost Comparison
14 Day Expression Analysis with Fuse-IT-mRNA
CleanCap EGFP mRNA
iPS derived cardiomyocytes Cor.-4U, axiogenesis, 6 minute fusion, 0.5ug of mRNA

References
 

  1. Abbas et al. Proc Natl Acad Sci USA. 2017; 114 (11): E2106-E2115

  2. Katibah et al. Proc Natl Acad Sci USA. 2014; 111 (33): 12025-30

  3. Schuberth-Wagner et al. Immunity. 2015; 42 (1): 41-45

  4. Kuge, H. et al. (1998). Nucleic Acids Res. 26, 3208-3214
     

Products containing the CleanCap™ technology are for research use only. Not for use in diagnostic or therapeutic procedures. Use of CleanCap™ technology may be covered by one or more patents or pending Patent Applications. https://www.trilinkbiotech.com/cleancap/license.asp

Want more Information?

Fill out the table with your inquiry and we will follow up with you ASAP

10770 Wateridge Cir 

San Diego, CA 92121

Tel: (800) 863-6801

  • LinkedIn
  • White Twitter Icon
  • White Facebook Icon
  • YouTube

© 2017 TriLink Biotechnologies